文献速递银屑病与炎症性皮肤病

布罗达鲁单抗治疗斑块状银屑病:104周真实世界有效性、安全性及初始应答与药物生存的临床预测因素

Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-01-04

该单中心回顾性研究纳入91例中重度斑块状银屑病患者,评估布罗达鲁单抗治疗104周的有效性与安全性。第12/16周PASI90/100达81.1%/66.0%,第104周升至87.1%/80.7%,84.9%达绝对PASI≤1。1年和2年药物生存概率分别为87.6%和77.32%,初始应答者和抗IL17初治者药物生存更优。

要点

  • 第12/16周PASI90/100达81.1%/66.0%,第104周升至87.1%/80.7%。
  • 1年和2年药物生存概率分别为87.6%和77.32%。
  • 初始应答者和抗IL17初治者药物生存更优,关节痛是导致停药最常见的不良事件。

核心结论

  • 本研究证实布罗达鲁单抗在真实世界环境中具有高有效性和良好的安全性。

研究设计与样本

  • 单中心回顾性研究,纳入91例接受布罗达鲁单抗治疗的中重度斑块状银屑病患者,评估第12/16、24、52和104周的PASI90/100及绝对PASI≤1/3。

主要发现

  • 第12/16周PASI90/100达81.1%/66.0%,第104周PASI90/100达87.1%/80.7%,84.9%患者达绝对PASI≤1。
  • 超过3种合并症、既往使用超过2种系统药物和肥胖倾向为「超级应答」的负面预测因素。
  • 既往暴露于IL17抑制剂对PASI<1和PASI<3初始应答均无影响。
  • 1年和2年药物生存概率分别为87.6%和77.32%。
  • 初始应答者和抗IL17初治患者药物生存更优;24.2%患者停药,多因继发性失效,关节痛是导致停药最常见的不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brodalumab, a fully human IgG2k antibody blocking the receptor of IL17, is characterized by a rapid onset of action with high skin clearance rates in clinical trials. Since setting PASI90/100 or absolute PASI ≤ 3 as treatment goals have become attainable, evaluating the effectiveness and safety profile of biologic agents, such as brodalumab, in a real-world setting is essential. OBJECTIVE: The aim of this study was to evaluate the effectiveness and safety profile of brodalumab over a period of 104 weeks in everyday practice. Clinical predictive factors of initial (week 12/16) response to treatment and long-term drug survival were also investigated. METHODS: In this monocentric, retrospective study, PASI90/100 and absolute PASI ≤ 1/3 were assessed in 91 patients with moderate-to-severe skin psoriasis under brodalumab at weeks 12/16, 24, 52 and 104 of treatment. At week 12/16, patients with an absolute PASI ≤ 3 were defined as 'initial responders' and ≤1 as 'super-responders'. Clinical parameters, such as age, gender, BMI, comorbidities and previous systemic treatment, were assessed in order to predict 'super-responders'. Drug survival and its prognostic factors were also evaluated. RESULTS: PASI90/100 has reached 81.1/66.0% in week 12/16. This response rate increased at week 104, where 87.1/80.7% had PASI90/100 and 84.9% had absolute PASI ≤ 1. The presence of >3 comorbidities, prior treatment with >2 systemic agents and obesity tended to be negative predictive factors of 'super-response'. Previous exposure to IL17 inhibitors had no impact on both PASI < 1 and PASI < 3 initial response. One- and two-year drug survival probability was 87.6% and 77.32%, respectively. 'Initial responders' and anti-IL17 drug-naïve patients had better drug survival. Drug discontinuation occurred in 24.2%, mostly due to secondary failure, and arthralgia was the most common adverse event that led to discontinuation. CONCLUSIONS: Our study confirms the high effectiveness and good safety profile of brodalumab in the real-world setting.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Rompoti N, Politou M, Stefanaki I, et al. Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks. J Eur Acad Dermatol Venereol. 2023. PMID: 36562663. doi:10.1111/jdv.18825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。